Literature DB >> 22872748

Safe use of hemodialysis for dabigatran removal before cardiac surgery.

Matthew R Wanek1, Edward T Horn, Subbarao Elapavaluru, Samuel C Baroody, George Sokos.   

Abstract

OBJECTIVE: To describe a case in which hemodialysis was performed before cardiac transplantation in an attempt to reverse the effects of dabigatran and reduce the risk of bleeding associated with surgery. CASE
SUMMARY: A 59-year-old female with heart failure and atrial fibrillation was admitted for orthotropic heart transplant. She had been stable at home with continuous milrinone therapy 0.25 μg/kg/min, amiodarone 200 mg twice daily, and dabigatran 150 mg twice daily for stroke prevention secondary to atrial fibrillation. Upon notification of organ availability, the patient was admitted to the hospital for transplant surgery, with her last dose of dabigatran taken approximately 36 hours before admission. Coagulation studies indicated normal activated partial thromboplastin time, slightly elevated international normalized ratio of 1.2, and elevated thrombin time (TT) of 90.6 seconds (upper limit of normal 19.9 seconds). A hemodialysis catheter was emergently placed and dialysis was initiated. One hour after initiation, TT decreased to 65.5 seconds. After 2.5 hours of dialysis, TT further decreased to 60.2 seconds; at that time, the patient underwent transplantation with no abnormal bleeding during or following surgery. DISCUSSION: Minimal data exist on techniques to reverse the effects of dabigatran in cases of bleeding or emergent surgery. This case examines the efficacy of hemodialysis to decrease dabigatran's effect on clotting assays prior to surgery to reduce the risk of bleeding. In this case, a TT of 60.2 seconds with recent dabigatran administration did not result in abnormal bleeding associated with cardiac surgery.
CONCLUSIONS: To our knowledge, this case report represents the first published data on the effects of hemodialysis on dabigatran removal and reversal of anticoagulation associated with dabigatran before surgery. The routine use of preoperative hemodialysis in patients on dabigatran is not recommended; however, the potential efficacy in such circumstances is supported by the successful results in this case.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22872748     DOI: 10.1345/aph.1R081

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  20 in total

Review 1.  Update on Anticoagulation: What the Interventional Radiologist Needs to Know.

Authors:  Suneel D Kamath; Brandon J McMahon
Journal:  Semin Intervent Radiol       Date:  2016-06       Impact factor: 1.513

Review 2.  Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.

Authors:  Julie Kalabalik; Gail B Rattinger; Jesse Sullivan; Malgorzata Slugocki; Antonia Carbone; Anastasia Rivkin
Journal:  Drugs       Date:  2015-06       Impact factor: 9.546

Review 3.  [Perioperative management of anticoagulation].

Authors:  R Eisele; N Melzer; P Bramlage
Journal:  Chirurg       Date:  2014-06       Impact factor: 0.955

4.  [Consensus statement: Stroke prevention in nonvalvular atrial fibrillation in special consideration of the new direct oral anticoagulants].

Authors:  Ingrid Pabinger; Wilfried Lang; Franz Xaver Roithinger; Franz Weidinger; Sabine Eichinger-Hasenauer; Reinhold Glehr; Walter-Michael Halbmayer; Hans-Peter Haring; Bernd Jilma; Hans Christian Korninger; Sibylle Kozek-Langenecker; Paul Kyrle; Herbert Watzke; Ansgar Weltermann; Johann Willeit; Kurt Huber
Journal:  Wien Klin Wochenschr       Date:  2014-10-03       Impact factor: 1.704

Review 5.  Who, when, and how to reverse non-vitamin K oral anticoagulants.

Authors:  Konstantinos N Aronis; Elaine M Hylek
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

Review 6.  Enhanced elimination of dabigatran through extracorporeal methods.

Authors:  Nadia I Awad; Luigi Brunetti; David N Juurlink
Journal:  J Med Toxicol       Date:  2015-03

Review 7.  Reversal of novel oral anticoagulants in patients with major bleeding.

Authors:  Deborah M Siegal; Adam Cuker
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

8.  Pharmacometric characterization of dabigatran hemodialysis.

Authors:  Karl-Heinz Liesenfeld; Alexander Staab; Sebastian Härtter; Stephan Formella; Andreas Clemens; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

9.  Bilateral Spontaneous Hyphema, Vitreous Hemorrhage, and Choroidal Detachment With Concurrent Dabigatran Etexilate Therapy.

Authors:  Kevin Wang; Justis P Ehlers
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2016-01       Impact factor: 1.300

Review 10.  Dabigatran and kidney disease: a bad combination.

Authors:  Felix Knauf; C Michael Chaknos; Jeffrey S Berns; Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.